Item(by='sradman', descendants=None, kids=None, score=None, time=1611941400, title=None, item_type='comment', url=None, parent=25957820, text='The NIH news release <i>Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released</i> [1]:<p>&gt; An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.<p>&gt; The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the studyâ€™s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant.<p>[1] <a href="https:&#x2F;&#x2F;www.nih.gov&#x2F;news-events&#x2F;news-releases&#x2F;janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released" rel="nofollow">https:&#x2F;&#x2F;www.nih.gov&#x2F;news-events&#x2F;news-releases&#x2F;janssen-invest...</a>')